SHANGHAI, China, October 15–Avenzo Therapeutics, Inc. (“Avenzo”), a partner of Duality Biotherapeutics, Inc. (“DualityBio”, HKEX: 09606) and a clinical-stage biotechnology company developing next-generation oncology therapies, announced the acceptance of an abstract for poster presentation at the 38th Symposium on Molecular Targets and Cancer Therapeutics hosted by the European Organisation for Research and Treatment of Cancer (EORTC), the National Cancer Institute (NCI), and the American Association for Cancer Research (AACR). The EORTC-NCI-AACR Symposium will take place in Barcelona, Spain from November 18-20, 2026.

Avenzo will present preliminary safety, tolerability, and efficacy results from the ongoing Phase 1 portion of AVENTINE-1, a Phase 1/2 study evaluating AVZO-1418, its potentially differentiated EGFR/HER3 bispecific antibody-drug conjugate.

Details of the poster presentation are as follows:

 Abstract: 81

Title: Preliminary phase 1 results from AVENTINE-1, a phase 1/2 study of AVZO-1418, an EGFR-HER3 bispecific antibody-drug conjugate (BsADC) for the treatment of patients with locally advanced or metastatic solid tumors

Poster #: PB-081

Poster Session: Antibody-Drug Conjugates

Date and Time: Wednesday, November 18, 2026, 12:00 to 7:00 p.m. CET

Location: Exhibition Hall

About DualityBio

DualityBio is a clinical-stage innovative biopharmaceutical company focused on developing next-generation ADCs for patients with cancer and autoimmune diseases. The Company has successfully established multiple next-generation ADC technology platforms with global intellectual property rights. Based on deep research into disease biology, DualityBio has built a broad clinical-stage ADC pipeline and is conducting global multicenter clinical trials across approximately 20 countries, with more than 3,500 patients enrolled. The Company has also entered into multiple global licensing collaborations with leading pharmaceutical companies and innovative biopharmaceutical companies. As a global ADC innovation engine, DualityBio continues to develop next-generation ADCs, including bispecific ADCs, novel-mechanism payload ADCs and autoimmune disease ADCs.

 For more information, please visit: www.dualitybiologics.com

Media Contact: PR@dualitybiologics.com

Investor Contact: IR@dualitybiologics.com

Forward-Looking Statements

This press release contains statements that may be deemed to be "forward-looking statements" within the meaning of applicable securities laws. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "aims," "intends," "plans," "believes," "may," and similar expressions. Statements that are not historical facts, including statements about the beliefs, plans, objectives, and expectations of Duality Biotherapeutics, Inc. (the "Company") regarding its business, research and development programs, and product candidates, are forward-looking statements.Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to risks related to the Company’s research and development, clinical trials, regulatory approvals, commercialization, and general economic and industry conditions.All information provided in this press release is as of the date of this press release, and the Company does not undertake any obligation to update any forward-looking statement, except as required under applicable law or regulatory rules.